Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 05, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0001710340 | ||
Entity Registrant Name | Eton Pharmaceuticals, Inc. | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 001-38738 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 37-1858472 | ||
Entity Address, Address Line One | 21925 W. Field Parkway, Suite 235 | ||
Entity Address, City or Town | Deer Park | ||
Entity Address, State or Province | IL | ||
Entity Address, Postal Zip Code | 60010-7278 | ||
City Area Code | 847 | ||
Local Phone Number | 787-7361 | ||
Title of 12(b) Security | Common Stock, $0.001 par value | ||
Trading Symbol | ETON | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | false | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 84,700,000 | ||
Entity Common Stock, Shares Outstanding | 25,688,062 | ||
Auditor Firm ID | 170 | ||
Auditor Name | KMJ Corbin & Company LLP | ||
Auditor Location | Irvine, California |
Balance Sheets
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Current assets: | ||
Cash and cash equivalents | $ 21,388 | $ 16,305 |
Accounts receivable, net | 3,411 | 1,852 |
Inventories | 911 | 557 |
Prepaid expenses and other current assets | 1,129 | 1,290 |
Total current assets | 26,839 | 20,004 |
Property and equipment, net | 58 | 72 |
Intangible assets, net | 4,739 | 4,754 |
Operating lease right-of-use assets, net | 92 | 188 |
Other long-term assets, net | 12 | 12 |
Total assets | 31,740 | 25,030 |
Current liabilities: | ||
Accounts payable | 1,848 | 1,766 |
Current portion of long-term debt, net of discount | 5,380 | 1,033 |
Accrued liabilities | 9,013 | 3,662 |
Total current liabilities | 16,241 | 6,461 |
Long-term debt, net of discount and including accrued fees | 0 | 5,384 |
Operating lease liabilities, net of current portion | 22 | 107 |
Total liabilities | 16,263 | 11,952 |
Commitments and contingencies (Note 14) | ||
Stockholders’ equity | ||
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,688,062 and 25,353,119 shares issued and outstanding at December 31, 2023 and 2022, respectively | 26 | 25 |
Additional paid-in capital | 119,521 | 116,187 |
Accumulated deficit | (104,070) | (103,134) |
Total stockholders’ equity | 15,477 | 13,078 |
Total liabilities and stockholders’ equity | $ 31,740 | $ 25,030 |
Balance Sheets (Parentheticals)
Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 50,000,000 | 50,000,000 |
Common stock, issued (in shares) | 25,688,062 | 25,353,119 |
Common stock, outstanding (in shares) | 25,688,062 | 25,353,119 |
Statements of Operations
Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total net revenues | $ 31,642 | $ 21,251 | $ 21,832 |
Cost of Sales: | |||
Total cost of sales | 10,581 | 6,933 | 2,827 |
Gross profit | 21,061 | 14,318 | 19,005 |
Operating expenses: | |||
Research and development | 3,322 | 3,996 | 6,235 |
General and administrative | 18,931 | 18,582 | 14,265 |
Total operating expenses | 22,253 | 22,578 | 20,500 |
Loss from operations | (1,192) | (8,260) | (1,495) |
Other income (expense): | |||
Interest and other income (expense), net | 503 | (761) | (1,006) |
Gain on PPP loan forgiveness | 0 | 0 | 365 |
Gain on equipment sale | 0 | 0 | 181 |
Loss before income tax expense | (689) | (9,021) | (1,955) |
Income tax expense | 247 | 0 | 0 |
Net loss | $ (936) | $ (9,021) | $ (1,955) |
Net loss per share, basic and diluted (in dollars per share) | $ (0.04) | $ (0.36) | $ (0.08) |
Weighted average number of common shares outstanding, basic and diluted (in shares) | 25,645,366 | 25,145,657 | 25,207,299 |
License [Member] | |||
Revenues: | |||
Total net revenues | $ 5,500 | $ 10,000 | $ 19,000 |
Cost of Sales: | |||
Total cost of sales | 1,000 | 1,640 | 1,500 |
Product Sales and Royalties [Member] | |||
Revenues: | |||
Total net revenues | 26,142 | 11,251 | 2,832 |
Cost of Sales: | |||
Total cost of sales | $ 9,581 | $ 5,293 | $ 1,327 |
Statements of Stockholders' Equ
Statements of Stockholders' Equity - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balances, shares (in shares) at Dec. 31, 2020 | 24,312,808 | |||
Balances at Dec. 31, 2020 | $ 24 | $ 107,797 | $ (92,158) | $ 15,663 |
Stock-based compensation, shares (in shares) | 0 | |||
Stock-based compensation | $ 0 | 3,381 | 0 | 3,381 |
Stock option exercises, shares (in shares) | 144,233 | |||
Stock option exercises | $ 1 | 338 | 0 | 339 |
Employee stock purchase plan, shares (in shares) | 49,155 | |||
Employee stock purchase plan | $ 0 | 202 | 0 | 202 |
Common stock issued related to restricted stock units, shares (in shares) | 25,000 | |||
Common stock issued related to restricted stock units | $ 0 | 0 | 0 | 0 |
Stock warrant exercises, shares (in shares) | 94,808 | |||
Stock warrant exercises | $ 0 | 0 | 0 | 0 |
Net income (loss) | $ 0 | 0 | (1,955) | (1,955) |
Balances, shares (in shares) at Dec. 31, 2021 | 24,626,004 | |||
Balances at Dec. 31, 2021 | $ 25 | 111,718 | (94,113) | 17,630 |
Stock-based compensation, shares (in shares) | 0 | |||
Stock-based compensation | $ 0 | 4,218 | 0 | 4,218 |
Stock option exercises, shares (in shares) | 25,000 | |||
Stock option exercises | $ 0 | 35 | 0 | $ 35 |
Employee stock purchase plan, shares (in shares) | 69,884 | 69,884 | ||
Employee stock purchase plan | $ 0 | 171 | 0 | $ 171 |
Stock warrant exercises, shares (in shares) | 632,231 | |||
Stock warrant exercises | $ 0 | 45 | 0 | 45 |
Net income (loss) | $ 0 | 0 | (9,021) | (9,021) |
Balances, shares (in shares) at Dec. 31, 2022 | 25,353,119 | |||
Balances at Dec. 31, 2022 | $ 25 | 116,187 | (103,134) | 13,078 |
Stock-based compensation | $ 0 | 3,137 | 0 | $ 3,137 |
Stock option exercises, shares (in shares) | 407,808 | |||
Employee stock purchase plan, shares (in shares) | 86,782 | 86,782 | ||
Employee stock purchase plan | $ 0 | 229 | 0 | $ 229 |
Net income (loss) | $ 0 | 0 | (936) | (936) |
Stock option exercises and vesting of restricted stock units (in shares) | 299,028 | |||
Stock option exercises and vesting of restricted stock units | $ 1 | 148 | 0 | $ 149 |
Shares withheld related to net share settlement of stock option exercises (in shares) | (50,867) | (50,867) | ||
Shares withheld related to net share settlement of stock option exercises | $ 0 | (180) | 0 | $ (180) |
Balances, shares (in shares) at Dec. 31, 2023 | 25,688,062 | |||
Balances at Dec. 31, 2023 | $ 26 | $ 119,521 | $ (104,070) | $ 15,477 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cash flows from operating activities | |||
Net income (loss) | $ (936) | $ (9,021) | $ (1,955) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
Stock-based compensation | 3,137 | 4,218 | 3,381 |
Depreciation and amortization | 901 | 1,774 | 462 |
Debt discount amortization | 117 | 127 | 148 |
Gain on forgiveness of PPP loan | 0 | 0 | (365) |
Gain on sale of equipment | 0 | 0 | (181) |
Changes in operating assets and liabilities: | |||
Accounts receivable | (1,559) | 3,619 | (5,423) |
Inventories | (354) | (7) | 692 |
Prepaid expenses and other assets | 161 | 1,902 | (1,026) |
Accounts payable | 53 | (8) | (570) |
Accrued liabilities | 5,295 | 2,217 | 116 |
Net cash provided by (used in) operating activities | 6,815 | 4,821 | (4,721) |
Cash used in investing activities | |||
Proceeds from sale of equipment | 0 | 0 | 700 |
Purchases of property and equipment | 0 | (38) | (9) |
Purchase of product licensing rights | (775) | (2,750) | (3,250) |
Net cash used in investing activities | (775) | (2,788) | (2,559) |
Cash flows from financing activities | |||
Debt paydown | (1,155) | (385) | (150) |
Net proceeds from employee stock purchase plan and stock option and stock warrant exercises | 198 | 251 | 541 |
Net cash (used in) provided by financing activities | (957) | (134) | 391 |
Change in cash and cash equivalents | 5,083 | 1,899 | (6,889) |
Cash and cash equivalents at beginning of year | 16,305 | 14,406 | 21,295 |
Cash and cash equivalents at end of year | 21,388 | 16,305 | 14,406 |
Supplemental disclosures of cash flow information | |||
Cash paid for interest | 842 | 730 | 815 |
Cash paid for income taxes | 247 | 0 | 0 |
Supplemental disclosures of non-cash investing and financing activities: | |||
Adjustment of operating lease right-of-use assets and liabilities due to tenant allowance | 29 | 0 | 0 |
Right-of-use assets obtained in exchange for lease liabilities | $ 0 | $ 188 | $ 0 |
Note 1 - Company Overview
Note 1 - Company Overview | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1 Company Overview Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has four 1 1 three 400, 600, |
Note 2 - Liquidity Consideratio
Note 2 - Liquidity Considerations | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Liquidation Basis of Accounting [Text Block] | Note 2 Liquidity Considerations As of December 31, 2023 December 31, 2023 To date, the Company has generated revenues from multiple products and expects further growth in 2024 December 31, 2023 twelve no may may |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 3 Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying financial statements in accordance with GAAP. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not Segment Information The Company operates the business on the basis of a single reportable segment, which is the business of developing and commercializing prescription drug products. The Company’s chief operating decision-maker is the CEO, who evaluates the Company as a single operating segment. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The Company considers historical collection rates and the current financial status of its customers, as well as macroeconomic and industry-specific factors when evaluating potential credit losses. Historically, the Company's accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of specialty pharmacies and large wholesale pharmaceutical distributors. Given the size and creditworthiness of these customers, we have not not December 31, 2023 2022 Inventories The Company values its inventories at the lower of cost or net realizable value using the first first December 31, 2023 2022 December 31, 2023 2022, December 31, 2023 2022 Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives. Computer hardware and software is depreciated over three five not Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 November 2021, ten 2019 five 14 June 2022 six December 31, 2022. Q1 2022 five three June 30, 2022. September 2022, five October 2023, five December 31, 2023 December 31, 2023, 2022 2021 five 2024 2028 Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739 Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023, 2022 2021 Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method. Leases The Company accounts for leases in accordance with ASC Topic 842 not The Company measures right-of-use assets based on the corresponding lease liabilities adjusted for (i) any prepayments made to the lessor at or before the commencement date, (ii) initial direct costs it incurs, and (iii) any incentives under the lease. In addition, the Company evaluates the recoverability of its right-of-use assets for possible impairment in accordance with its long-lived assets policy. Operating leases are reflected on the balance sheets as operating lease right-of-use assets, current accrued liabilities and long-term operating lease liabilities. The Company does not December 31, 2023 2022 The Company commences recognizing operating lease expense when the lessor makes the underlying asset available for use by the Company and the operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are expensed as incurred. The Company does not twelve Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Concentrations of Credit Risk, Sources of Supply and Significant Customers The Company is subject to credit risk for its cash and cash equivalents which are invested in money market funds and U.S. treasury bills from time to time. The Company maintains its cash and cash equivalent balances with one The Company is dependent on third The Company is also subject to credit risk from its accounts receivable related to product sales as it extends credit based on an evaluation of the customer’s financial condition, and collateral is not no December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 2023 December 31, 2023 2022 December 31, 2022 Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 606 606, 606, five At contract inception, once the contract is determined to be within the scope of ASC 606, The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve not twelve Milestone Payments not not not Royalties Significant Financing Component one The Company sells its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nisitinone products to pharmacy distributor customers which provide order fulfilment and inventory storage/distribution services. The Company may third “3PL” 3PL 3PL no For its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are estimated and recorded as a reduction of net revenues at the date of sale/shipment. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell products at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. Because of the shelf life of the product and the Company’s lengthy return period, there may The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks and the impact of other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no The Company stores its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone inventory at its pharmacy distributor customer locations, and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. The Company may not Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. Cost of Product Sales Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third 3PL 3PL Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as Series A Preferred, unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. No 2023 2022 2021 December 31, 2023, 2022 2021 9 Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 718 The Company estimates the fair value of stock-based option awards using the BSM. The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero zero Income Taxes As part of the process of preparing the Company’s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not December 31, 2023 2022 The Company accounts for income taxes under the provisions of ASC 740 December 31, 2023 2022 no December 31, 2023 2022 not December 31, 2023, 2022 2021 December 31, 2023 2017 2023 Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2023 2022 Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and long-term debt obligation. The carrying amounts of these financial instruments, except for the long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the long-term debt obligation approximate its fair value. Impact of Recent Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, No. 2021 01, Reference Rate Reform (Topic 848 2021 01" No. 2020 04 No. 2021 01 No. 2020 04 No. 2021 01 December 31, 2022. December 2022, No. 2022 06, Reference Rate Reform (Topic 848 Topic 848 848 December 31, 2024. August 22, 2023. no In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 316 may No. 2016 13, No. 2018 19, Codification Improvements to Topic 326, not No. 2016 13, No. 2019 04 not No. 2016 13 not January 1, 2023 not no |
Note 4 - Property and Equipment
Note 4 - Property and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 4 Property and Equipment Property and equipment consist of the following: December 31, December 31, 2023 2022 Computer hardware and software $ 187 $ 177 Furniture and fixtures 111 112 Equipment 52 52 Leasehold improvements 103 71 Construction in progress — 12 453 424 Less: accumulated depreciation and amortization (395 ) (352 ) Property and equipment, net $ 58 $ 72 Depreciation expense for the years ended December 31, 2023, 2022 2021 |
Note 5 - Debt
Note 5 - Debt | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Long-Term Debt [Text Block] | Note 5 Debt SWK Loan In November 2019, second 100. March 2020, 14 March 2020 6 100 September 2020. August 2020. February 2022 three November 2024 February 2021, not In connection with the initial $5,000 borrowed in November 2019, seven In connection with the additional $2,000 borrowed in August 2020, seven These warrants (the “SWK Warrants”) are exercisable immediately and have a term of seven In April 2022, May 2023 3 12 December 31, 2022. June 2023, August 2023 The Company recorded interest expense of $1,060, $955 and $1,042 in 2023, 2022 2021 December 31, 2023 2022 Note 5 Debt (continued) The table below reflects the future annual payments for the SWK loan principal and interest as of December 31, 2023 Amount 2024 6,483 Total payments 6,483 Less: amount representing interest (1,023 ) Loan payable, gross 5,460 Less: unamortized discount (80 ) Debt, net of unamortized discount $ 5,380 PPP loan On May 4, 2020, May 20, 2021, December 31, 2021 EIDL loan On July 21, 2020, July 2021. |
Note 6 - Common Stock
Note 6 - Common Stock | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | Note 6 Common Stock The Company has 50,000,000 authorized shares of $0.001 par value common stock under its Amended and Restated Certificate of Incorporation. Note 6 Common Stock (continued) For the years ended December 31, 2023 2022 2018 8 December 31, 2023. December 31, 2023 2022 December 31, 2023 April 2021, 2022, |
Note 7 - Common Stock Warrants
Note 7 - Common Stock Warrants | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Stockholders' Equity Note, Warrants or Rights Warrants Disclosure [TextBlock] | Note 7 Common Stock Warrants Listed below is a summary of warrants outstanding as of December 31, 2023 Description of Warrants No. of Shares Exercise Price SWK Warrants – Debt (Tranche #1) 51,239 $ 5.86 SWK Warrants – Debt (Tranche #2) 18,141 $ 6.62 Total 69,380 6.05 (Avg) The holders of these warrants or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of their shares that are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the investors. On June 26, 2022, 2017 December 26, 2022 No December 31, 2022. A rollforward of the warrants outstanding is listed in the table below: No. of Shares Balance as of the beginning of the year 483,380 Expiration of National Securities Corp – November 2018 issuance (414,000 ) Balance as of the end of the year 69,380 There were 1,067,242 warrants exercised on a cashless basis in 2022 2021 2022 2021. 2023. |
Note 8 - Share-based Payment Aw
Note 8 - Share-based Payment Awards | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | Note 8 Share-Based Payment Awards The Company’s board of directors and stockholders approved the Eton Pharmaceuticals, Inc. 2017 May 2017 ( “2017 November 2018, 2018 “2018 2017 2017 2018 2018 December 31, 2023 Note 8 Share-Based Payment Awards (continued) Shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards under the 2018 2018 January 1, 2019 January 1, 2028, December 31, January 1, 2021, December 31, 2020. January 1, 2022, December 31, 2021. January 1, 2023, December 31, 2022. not To date, all stock options issued have been non-qualified stock options, and the exercise prices were set at the fair value for the shares at the dates of grant. Options typically have a ten July 2017 July 2022 not five not not In July 2022 September 2022, two one May 2022 July 2022. 90 may April 2023. No December 31, 2022. For the years ended December 31, 2023, 2022 2021 Stock Options The following table summarizes stock option activity during the year ended December 31, 2023 Weighted Average Weighted Average Remaining Exercise Contractual Aggregate Intrinsic Shares Price Term Value Options outstanding as of January 1, 2023 4,402,292 $ 4.71 Issued 1,108,291 3.51 Exercised (407,808 ) 2.23 Forfeited/Cancelled (263,549 ) 5.94 Options outstanding as of December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 Options exercisable at December 31, 2023 3,399,896 $ 4.78 6.7 $ 2,432 Options vested and expected to vest at December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock at December 31. 2023 Note 8 Share-Based Payment Awards (continued) There were 207,626 and 25,000 shares issued for exercise of stock options during the years ended December 31, 2023 2022 The assumptions used to calculate the estimated fair value of options granted during the years ended December 31, 2023, 2022 2021 December 31, 2023 December 31, 2022 December 31, 2021 Expected dividends — % — % — % Expected volatility 70 % 70 % 70 - 80 % Risk-free interest rate 3.5 - 4.7 % 1.5 - 3.9 % 0.9 - 1.4 % Expected term (in years) 6.3 5.9 6.0 Weighted average grant date fair value $ 2.32 $ 2.32 $ 5.64 Expected Term — The Company has opted to use the “simplified method” for estimating the expected term of options granted to employees and directors, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The expected term of options granted to non-employees equals the contractual life of the options. Expected Volatility — Expected volatilities are based on the Company's historical volatility subsequent to our IPO, which we believe represents the most accurate basis for estimating expected future volatility under the current conditions. Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options. Expected Dividend — The Company has not not Fair value of Common Stock —The Company uses the closing stock price on the date of grant for the fair value of the common stock. As of December 31, 2023 Restricted Stock Units (RSUs) The following table summarizes restricted stock unit activity during the year ended December 31, 2023 Weighted Average Grant-Date Number of Units Fair Value Per Unit Outstanding and unvested as of January 1, 2023 369,606 $ 2.63 Granted — — Vested (91,402 ) $ 2.63 Forfeited (4,000 ) $ 2.63 Outstanding and unvested as of December 31, 2023 274,204 $ 2.63 Stock-based compensation related to RSUs was $239 and $114 for the years ended December 31, 2023 2022 December 31, 2023 Note 8 Share-Based Payment Awards (continued) Employee Stock Purchase Plan In December 2018, January 1 December 31 The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of ( 1 first 2 twelve two six June 10 December 10 six twelve The Company recorded an expense of $135, $128, and $73 in 2023, 2022 2021 December 31, 2023 2022 2023, 2022 2021 2023 2022 December 31, 2023 2022 December 31, 2023 |
Note 9 - Basic and Diluted Net
Note 9 - Basic and Diluted Net Loss per Common Share | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | Note 9 Basic and Diluted Net Loss per Common Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and RSUs, and warrants at December 31, 2023, 2022 2021 The following table shows the computation of basic and diluted net loss per common share: Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Net loss $ (936 ) $ (9,021 ) $ (1,955 ) Weighted average common shares outstanding (basic and diluted) 25,645,366 25,145,657 25,207,299 Net loss per common share (basic and diluted) $ (0.04 ) $ (0.36 ) $ (0.08 ) |
Note 10 - Related-party Transac
Note 10 - Related-party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 10 Related-Party Transactions Harrow The Chief Executive Officer of Harrow Health, Inc. (“Harrow”) was a member of the Company’s board of directors until March 17, 2021 April 2021 December 31, 2023 In March 2021, May 2021 Chief Executive Officer The CEO has a partial interest in a company that the Company has partnered with for its EM- 100/Alaway The Company acquired the exclusive rights to sell the EM- 100 August 11, 2017 first two On February 18, 2019, 100, two one first one first first December 31, 2023 100 February 18, 2019 twelve September 2020, December 31, 2023 December 31, 2022 March 24, 2023. |
Note 11 - Leases
Note 11 - Leases | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | Note 11 Leases The Company recognizes a right-of-use (“ROU”) asset and a lease liability on the balance sheet for substantially all leases, including operating leases, and separates lease components from non-lease components related to its office space lease. In January 2018, October 2020, two March 2023 November 2022, two March 2025 In March 2018, March 2018. November 2020, June 2021 not The Company does not 1 2 3 not not The Company’s leases do not October 2020, November 2022, Note 11 Leases (continued) The Company’s operating lease cost as presented in the “Research and Development” and “General and Administrative” captions in the statements of operations was $0, $0, and $9 and $67, $82, and $86 for the years ended December 31, 2023, 2022 2021 December 31, 2023, 2022 2021 December 31, 2023, 2022, 2021, December 31, 2023, 2022 2021 December 31, 2023 The table below presents the lease-related assets and liabilities recorded on the balance sheet as of December 31, 2023 Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 92 Total leased assets $ 92 Liabilities Operating lease liabilities, current Accrued liabilities $ 53 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 22 Total operating lease liabilities $ 75 The Company’s future annual lease commitments as of December 31, 2023 Total 2024 2025 2026 Undiscounted lease payments $ 81 $ 58 $ 23 $ — Less: Imputed interest (6 ) Total lease liabilities $ 75 |
Note 12 - Income Taxes
Note 12 - Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 12 Income Taxes The provision for income taxes for the Company consists of the following for the years ended December 31, 2023, 2022 2021 Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Current: Federal $ 61 $ — $ — State 186 — — Total current expense 247 — — Deferred: Federal (85 ) 2,272 460 State (31 ) 812 185 Change in valuation allowance 116 (3,084 ) (645 ) Total deferred expense — — — Total provision $ 247 $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Note 12 Income Taxes (continued) The significant components of the Company’s deferred tax assets as of December 31, 2023 2022 December 31, December 31, 2023 2022 Net operating losses $ 15,447 $ 17,183 Stock-based expenses 3,372 3,090 Accruals and other 2,697 1,359 Total deferred tax assets 21,516 21,632 Valuation allowance (21,516 ) (21,632 ) Net deferred tax assets $ — $ — Based on the uncertainty of future taxable income at this time management believes a 100% valuation reserve for the $21,516 and $21,632 deferred tax assets at December 31, 2023 2022 A reconciliation of the statutory federal tax rate to effective tax rate is shown below: Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Provision (benefit) at statutory rate 21.0 % (21.0 )% (21.0 )% Permanent items (primarily warrants and stock compensation) 39.1 (3.3 ) (2.5 ) State tax benefit 6.5 (8.7 ) (9.5 ) Federal rate change — — — Other items — — — Increase (decrease) in valuation allowance (30.7 ) 33.0 33.0 Income tax expense 35.9 % — % — % The Company has a federal and state NOL carryforward of $54,190 as of December 31, 2023 December 31, 2017 may 80% 2029. In addition, under Sections 382 383 1986, 50% three may |
Note 13 - Employee Savings Plan
Note 13 - Employee Savings Plan | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 13 Employee Savings Plan The Company established an employee savings plan pursuant to Section 401 January 1, 2018. December 31, 2023, 2022 2021 |
Note 14 - Commitments and Conti
Note 14 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 14 Commitments and Contingencies Legal The Company is subject to legal proceedings and claims that may not may License and Product Development Agreements The Company has entered into various agreements in addition to those discussed above which are described below. The three three 2021, three June 2023 Prior to January 1, 2022, third 101 November 2021, December 2021. December 31, 2021 January 2022. On January 23, 2019, 104” 104. 104 November 2022. Note 14 Commitments and Contingencies (continued) In March 2020, September 2020, For the initial licensing milestone fee, the Company paid Diurnal $3,500 in cash and issued 379,474 shares of its common stock to Diurnal which were valued at $1,264 based on the Company’s closing stock price of $3.33 on March 26, 2020. 2023 January 2024 December 2023, In June 2021, March 2022 In October 2021, October 2021. December 2021. In June 2022, twelve December 31, 2022. twelve December 31, 2022. In September 2022, January 2022. November 2023, In March 2023, 600 July 2023 first In October 2023, May 2023. Indemnification As permitted under Delaware law and in accordance with the Company’s Amended and Restated Bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not December 31, 2023 2022 |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Dec. 31, 2023 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 9B. Insider Trading Arrangements and Related Disclosure During the three December 31, 2023, none 10b5 1 10b5 1 408 We are committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, we have adopted our Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by our directors, officers, employees and designated contractors. We believe our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. A copy of our Insider Trading Policy, including any amendments thereto, is filed as Exhibit 19.1 10 9C. Not |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The Company has prepared the accompanying financial statements in accordance with GAAP. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not |
Segment Reporting, Policy [Policy Text Block] | Segment Information The Company operates the business on the basis of a single reportable segment, which is the business of developing and commercializing prescription drug products. The Company’s chief operating decision-maker is the CEO, who evaluates the Company as a single operating segment. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three |
Accounts Receivable [Policy Text Block] | Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The Company considers historical collection rates and the current financial status of its customers, as well as macroeconomic and industry-specific factors when evaluating potential credit losses. Historically, the Company's accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of specialty pharmacies and large wholesale pharmaceutical distributors. Given the size and creditworthiness of these customers, we have not not December 31, 2023 2022 |
Inventory, Policy [Policy Text Block] | Inventories The Company values its inventories at the lower of cost or net realizable value using the first first December 31, 2023 2022 December 31, 2023 2022, December 31, 2023 2022 |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives. Computer hardware and software is depreciated over three five not Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 November 2021, ten 2019 five 14 June 2022 six December 31, 2022. Q1 2022 five three June 30, 2022. September 2022, five October 2023, five December 31, 2023 December 31, 2023, 2022 2021 five 2024 2028 Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739 |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023, 2022 2021 |
Debt, Policy [Policy Text Block] | Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method. |
Lessee, Leases [Policy Text Block] | Leases The Company accounts for leases in accordance with ASC Topic 842 not The Company measures right-of-use assets based on the corresponding lease liabilities adjusted for (i) any prepayments made to the lessor at or before the commencement date, (ii) initial direct costs it incurs, and (iii) any incentives under the lease. In addition, the Company evaluates the recoverability of its right-of-use assets for possible impairment in accordance with its long-lived assets policy. Operating leases are reflected on the balance sheets as operating lease right-of-use assets, current accrued liabilities and long-term operating lease liabilities. The Company does not December 31, 2023 2022 The Company commences recognizing operating lease expense when the lessor makes the underlying asset available for use by the Company and the operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are expensed as incurred. The Company does not twelve |
Patent Costs [Policy Text Block] | Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of Credit Risk, Sources of Supply and Significant Customers The Company is subject to credit risk for its cash and cash equivalents which are invested in money market funds and U.S. treasury bills from time to time. The Company maintains its cash and cash equivalent balances with one The Company is dependent on third The Company is also subject to credit risk from its accounts receivable related to product sales as it extends credit based on an evaluation of the customer’s financial condition, and collateral is not no December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 2023 December 31, 2023 2022 December 31, 2022 |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 606 606, 606, five At contract inception, once the contract is determined to be within the scope of ASC 606, The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve not twelve Milestone Payments not not not Royalties Significant Financing Component one The Company sells its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nisitinone products to pharmacy distributor customers which provide order fulfilment and inventory storage/distribution services. The Company may third “3PL” 3PL 3PL no For its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are estimated and recorded as a reduction of net revenues at the date of sale/shipment. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell products at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. Because of the shelf life of the product and the Company’s lengthy return period, there may The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks and the impact of other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no The Company stores its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone inventory at its pharmacy distributor customer locations, and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. The Company may not Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. |
Cost of Goods and Service [Policy Text Block] | Cost of Product Sales Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third 3PL 3PL |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not |
Earnings Per Share, Policy [Policy Text Block] | Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as Series A Preferred, unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. No 2023 2022 2021 December 31, 2023, 2022 2021 9 |
Share-Based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 718 The Company estimates the fair value of stock-based option awards using the BSM. The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero zero |
Income Tax, Policy [Policy Text Block] | Income Taxes As part of the process of preparing the Company’s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not December 31, 2023 2022 The Company accounts for income taxes under the provisions of ASC 740 December 31, 2023 2022 no December 31, 2023 2022 not December 31, 2023, 2022 2021 December 31, 2023 2017 2023 Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2023 2022 |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and long-term debt obligation. The carrying amounts of these financial instruments, except for the long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the long-term debt obligation approximate its fair value. |
New Accounting Pronouncements, Policy [Policy Text Block] | Impact of Recent Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, No. 2021 01, Reference Rate Reform (Topic 848 2021 01" No. 2020 04 No. 2021 01 No. 2020 04 No. 2021 01 December 31, 2022. December 2022, No. 2022 06, Reference Rate Reform (Topic 848 Topic 848 848 December 31, 2024. August 22, 2023. no In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 316 may No. 2016 13, No. 2018 19, Codification Improvements to Topic 326, not No. 2016 13, No. 2019 04 not No. 2016 13 not January 1, 2023 not no |
Note 3 - Summary of Significa_2
Note 3 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739 |
Note 4 - Property and Equipme_2
Note 4 - Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, December 31, 2023 2022 Computer hardware and software $ 187 $ 177 Furniture and fixtures 111 112 Equipment 52 52 Leasehold improvements 103 71 Construction in progress — 12 453 424 Less: accumulated depreciation and amortization (395 ) (352 ) Property and equipment, net $ 58 $ 72 |
Note 5 - Debt (Tables)
Note 5 - Debt (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
SWK Credit Agreement [Member] | |
Notes Tables | |
Schedule of Maturities of Long-Term Debt [Table Text Block] | Amount 2024 6,483 Total payments 6,483 Less: amount representing interest (1,023 ) Loan payable, gross 5,460 Less: unamortized discount (80 ) Debt, net of unamortized discount $ 5,380 |
Note 7 - Common Stock Warrants
Note 7 - Common Stock Warrants (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Description of Warrants No. of Shares Exercise Price SWK Warrants – Debt (Tranche #1) 51,239 $ 5.86 SWK Warrants – Debt (Tranche #2) 18,141 $ 6.62 Total 69,380 6.05 (Avg) |
Schedule of Rollforward of Warrants Outstanding [Table Text Block] | No. of Shares Balance as of the beginning of the year 483,380 Expiration of National Securities Corp – November 2018 issuance (414,000 ) Balance as of the end of the year 69,380 |
Note 8 - Share-based Payment _2
Note 8 - Share-based Payment Awards (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Weighted Average Weighted Average Remaining Exercise Contractual Aggregate Intrinsic Shares Price Term Value Options outstanding as of January 1, 2023 4,402,292 $ 4.71 Issued 1,108,291 3.51 Exercised (407,808 ) 2.23 Forfeited/Cancelled (263,549 ) 5.94 Options outstanding as of December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 Options exercisable at December 31, 2023 3,399,896 $ 4.78 6.7 $ 2,432 Options vested and expected to vest at December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | December 31, 2023 December 31, 2022 December 31, 2021 Expected dividends — % — % — % Expected volatility 70 % 70 % 70 - 80 % Risk-free interest rate 3.5 - 4.7 % 1.5 - 3.9 % 0.9 - 1.4 % Expected term (in years) 6.3 5.9 6.0 Weighted average grant date fair value $ 2.32 $ 2.32 $ 5.64 |
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | Weighted Average Grant-Date Number of Units Fair Value Per Unit Outstanding and unvested as of January 1, 2023 369,606 $ 2.63 Granted — — Vested (91,402 ) $ 2.63 Forfeited (4,000 ) $ 2.63 Outstanding and unvested as of December 31, 2023 274,204 $ 2.63 |
Note 9 - Basic and Diluted Ne_2
Note 9 - Basic and Diluted Net Loss per Common Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Net loss $ (936 ) $ (9,021 ) $ (1,955 ) Weighted average common shares outstanding (basic and diluted) 25,645,366 25,145,657 25,207,299 Net loss per common share (basic and diluted) $ (0.04 ) $ (0.36 ) $ (0.08 ) |
Note 11 - Leases (Tables)
Note 11 - Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Lessee, Operating Lease, Disclosure [Table Text Block] | Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 92 Total leased assets $ 92 Liabilities Operating lease liabilities, current Accrued liabilities $ 53 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 22 Total operating lease liabilities $ 75 |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Total 2024 2025 2026 Undiscounted lease payments $ 81 $ 58 $ 23 $ — Less: Imputed interest (6 ) Total lease liabilities $ 75 |
Note 12 - Income Taxes (Tables)
Note 12 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Current: Federal $ 61 $ — $ — State 186 — — Total current expense 247 — — Deferred: Federal (85 ) 2,272 460 State (31 ) 812 185 Change in valuation allowance 116 (3,084 ) (645 ) Total deferred expense — — — Total provision $ 247 $ — $ — |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, December 31, 2023 2022 Net operating losses $ 15,447 $ 17,183 Stock-based expenses 3,372 3,090 Accruals and other 2,697 1,359 Total deferred tax assets 21,516 21,632 Valuation allowance (21,516 ) (21,632 ) Net deferred tax assets $ — $ — |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Provision (benefit) at statutory rate 21.0 % (21.0 )% (21.0 )% Permanent items (primarily warrants and stock compensation) 39.1 (3.3 ) (2.5 ) State tax benefit 6.5 (8.7 ) (9.5 ) Federal rate change — — — Other items — — — Increase (decrease) in valuation allowance (30.7 ) 33.0 33.0 Income tax expense 35.9 % — % — % |
Note 2 - Liquidity Considerat_2
Note 2 - Liquidity Considerations (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Retained Earnings (Accumulated Deficit) | $ (104,070) | $ (103,134) | |
Net Income (Loss) Attributable to Parent | (936) | (9,021) | $ (1,955) |
Cash and Cash Equivalents, at Carrying Value | $ 21,388 | $ 16,305 |
Note 3 - Summary of Significa_3
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
Oct. 31, 2023 | Sep. 30, 2022 | Nov. 30, 2021 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2019 | Jun. 30, 2022 | |
Accounts Receivable, Allowance for Credit Loss | $ 129 | $ 262 | |||||||
Inventory Valuation Reserves | 76 | 62 | |||||||
Payments to Acquire Intangible Assets | 775 | 2,750 | $ 3,250 | ||||||
Finite-Lived Intangible Assets, Accumulated Amortization | 1,286 | ||||||||
Amortization of Intangible Assets | 790 | 1,617 | 204 | ||||||
Impairment, Long-Lived Asset, Held-for-Use | 0 | 0 | $ 0 | ||||||
Finance Lease, Liability | $ 0 | $ 0 | |||||||
Percentage for Valuation Reserve Against Deferred Tax Assets | 100% | 100% | |||||||
Unrecognized Tax Benefits | $ 0 | $ 0 | |||||||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | AnovoRx [Member] | |||||||||
Concentration Risk, Percentage | 78.20% | 45.50% | |||||||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | AnovoRx [Member] | |||||||||
Concentration Risk, Percentage | 97.40% | 79.80% | |||||||
Carglumic Acid Product Rights [Member] | |||||||||
Payments to Acquire Intangible Assets | $ 3,250 | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 10 years | ||||||||
Biorphen [Member] | |||||||||
Payments to Acquire Intangible Assets | $ 750 | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 5 years | ||||||||
Finite-Lived Intangible Assets, Accumulated Amortization | $ 275 | ||||||||
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year | $ 75 | ||||||||
Rezipres Product [Member] | |||||||||
Payments to Acquire Intangible Assets | $ 750 | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 5 years | ||||||||
Finite-Lived Intangible Assets, Accumulated Amortization | $ 738 | ||||||||
Betaine Anhydrous Product Rights [Member] | |||||||||
Payments to Acquire Intangible Assets | $ 2,125 | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 5 years | ||||||||
Nitisinone Product Rights [Member] | |||||||||
Payments to Acquire Intangible Assets | $ 650 | ||||||||
Finite-Lived Intangible Asset, Useful Life (Year) | 5 years | ||||||||
Furniture and Fixtures [Member] | |||||||||
Property, Plant and Equipment, Useful Life (Year) | 5 years |
Note 3 - Summary of Significa_4
Note 3 - Summary of Significant Accounting Policies - Schedule of Intangible Assets Amortization Expense (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
2024 | $ 880 |
2025 | 880 |
2026 | 880 |
2027 | 756 |
2028 | 423 |
Thereafter | 920 |
Total estimated amortization expense | $ 4,739 |
Note 4 - Property and Equipme_3
Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Depreciation | $ 44 | $ 66 | $ 155 |
Note 4 - Property and Equipme_4
Note 4 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Computer hardware and software | $ 187 | $ 177 |
Furniture and fixtures | 111 | 112 |
Equipment | 52 | 52 |
Leasehold improvements | 103 | 71 |
Construction in progress | 0 | 12 |
Property, Plant and Equipment, Gross | 453 | 424 |
Less: accumulated depreciation and amortization | (395) | (352) |
Property and equipment, net | $ 58 | $ 72 |
Note 5 - Debt (Details Textual)
Note 5 - Debt (Details Textual) | 1 Months Ended | 12 Months Ended | 33 Months Ended | ||||||||||||||
Apr. 05, 2022 USD ($) | May 20, 2021 USD ($) | Aug. 11, 2020 USD ($) | Jul. 21, 2020 USD ($) | May 04, 2020 USD ($) | Nov. 30, 2019 USD ($) $ / shares shares | Nov. 13, 2019 USD ($) | Aug. 31, 2020 USD ($) $ / shares shares | Nov. 30, 2019 USD ($) $ / shares shares | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) | Nov. 13, 2024 | Sep. 30, 2023 $ / shares | Jun. 26, 2022 $ / shares shares | Nov. 13, 2020 USD ($) | Mar. 31, 2020 USD ($) | |
Long-Term Debt, Gross | $ 5,460,000 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 467,242 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 3 | ||||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||
Long-Term Debt, Current Maturities | $ 5,380,000 | $ 1,033,000 | |||||||||||||||
Interest Expense | 1,060,000 | 955,000 | $ 1,042,000 | ||||||||||||||
Amortization of Debt Discount (Premium) | 117,000 | 127,000 | 148,000 | ||||||||||||||
Gain (Loss) on Extinguishment of Debt | 0 | 0 | 365,000 | ||||||||||||||
SWK Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 51,239 | 18,141 | 51,239 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5.86 | $ 6.62 | $ 5.86 | ||||||||||||||
Warrants and Rights Outstanding | $ 51,239 | $ 51,239 | |||||||||||||||
Fair Value Adjustment of Warrants | $ 94,000 | $ 226,000 | |||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 5.75 | $ 6.85 | $ 5.75 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 7 years | 7 years | 7 years | ||||||||||||||
SWK Warrants [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 95 | 95 | 95 | ||||||||||||||
SWK Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 | 0 | ||||||||||||||
SWK Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.8 | 0.4 | 1.8 | ||||||||||||||
SWK Credit Agreement [Member] | SWK Holdings Corporation [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | ||||||||||||||||
Proceeds from Issuance of Debt | $ 5,000,000 | 5,000,000 | |||||||||||||||
Debt Instrument, Covenant Agreement, Additional Amount | $ 5,000,000 | ||||||||||||||||
Debt Instrument, Covenant Requirements, Minimum Cash Balance | $ 3,000,000 | ||||||||||||||||
SWK Credit Agreement [Member] | SWK Holdings Corporation [Member] | Scenario, Plan [Member] | |||||||||||||||||
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed | 5.50% | ||||||||||||||||
The Amended Agreement [Member] | |||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 332,000 | $ 231,000 | |||||||||||||||
The Amended Agreement [Member] | SWK Holdings Corporation [Member] | |||||||||||||||||
Proceeds from Issuance of Debt | $ 2,000,000 | $ 2,000,000 | |||||||||||||||
Debt Instrument, Covenant Agreement, Additional Amount | $ 3,000,000 | ||||||||||||||||
Long-Term Debt, Gross | $ 2,000,000 | ||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8% | ||||||||||||||||
Debt Instrument, LIBOR Floor Rate | 2% | ||||||||||||||||
Long-Term Debt, Current Maturities | $ 1,033,000 | ||||||||||||||||
The Amended Agreement [Member] | SWK Holdings Corporation [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | |||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8.26% | ||||||||||||||||
Debt Instrument SOFR Floor Rate | 5% | ||||||||||||||||
Paycheck Protection Program Loan [Member] | |||||||||||||||||
Proceeds from Issuance of Debt | $ 361,000 | ||||||||||||||||
Interest Expense | $ 4,000 | ||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 365,000 | ||||||||||||||||
Economic Injury Disaster Loan Program [Member] | |||||||||||||||||
Proceeds from Issuance of Debt | $ 150,000 | ||||||||||||||||
Interest Expense | $ 6,000 |
Note 5 - Debt - Schedule of Fut
Note 5 - Debt - Schedule of Future Payments (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
2024 | $ 6,483 | |
Total payments | 6,483 | |
Less: amount representing interest | (1,023) | |
Long-Term Debt, Gross | 5,460 | |
Less: unamortized discount | (80) | |
Current portion of long-term debt, net of discount | $ 5,380 | $ 1,033 |
Note 6 - Common Stock (Details
Note 6 - Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | ||||
Apr. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2023 | Jun. 26, 2022 | |
Common Stock, Shares Authorized (in shares) | 50,000,000 | 50,000,000 | 50,000,000 | |||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 407,808 | |||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 50,867 | |||||
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation | $ 180 | |||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 25,000 | 86,782 | 69,884 | |||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares) | 91,402 | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 467,242 | |||||
Common Stock Warrants [Member] | ||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | 1,067,242 | 135,650 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 632,231 | 94,808 | ||||
The Two Thousand Eighteen Equity Incentive Plan Member | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 207,626 | 25,000 | ||||
The Two Thousand Eighteen Equity Incentive Plan Member | Cashless Stock Awards [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 407,808 |
Note 7 - Common Stock Warrant_2
Note 7 - Common Stock Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jun. 26, 2022 | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 467,242 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3 | |||
Common Stock Warrants [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 632,231 | 94,808 | ||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | 1,067,242 | 135,650 | |
Class of Warrant or Right, Exercised, Intrinsic Value | $ 2,367 | $ 806 | ||
General and Administrative Expense [Member] | ||||
Class of Warrant or Right, Modification Expense | $ 244 |
Note 7 - Common Stock Warrant_3
Note 7 - Common Stock Warrants - Schedule of Warrants Outstanding (Details) - $ / shares | Dec. 31, 2023 | Jun. 26, 2022 |
Outstanding (in shares) | 69,380 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3 | |
Weighted Average [Member] | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.05 | |
SWK Warrants – Debt – Tranche #1 [Member] | ||
Outstanding (in shares) | 51,239 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.86 | |
SWK Warrants – Debt – Tranche #2 [Member] | ||
Outstanding (in shares) | 18,141 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.62 |
Note 7 - Common Stock Warrant_4
Note 7 - Common Stock Warrants - Summary of Rollforward of The Warrants Outstanding (Details) | 12 Months Ended |
Dec. 31, 2023 shares | |
Balance (in shares) | 69,380 |
Placement Agent Warrants, 2017 Preferred Stock Offering [Member] | |
Balance (in shares) | 483,380 |
Class of Warrant or Right, Exercised During Period (in shares) | (414,000) |
Balance (in shares) | 69,380 |
Note 8 - Share-based Payment _3
Note 8 - Share-based Payment Awards (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2018 | Apr. 30, 2021 | Jul. 31, 2017 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jan. 01, 2023 | Jan. 01, 2022 | Jan. 01, 2021 | Dec. 31, 2020 | May 30, 2017 | |
Common Stock, Capital Shares Reserved for Future Issuance, Increase (in shares) | 1,014,124 | 985,040 | 972,512 | ||||||||
Common Stock, Shares, Outstanding (in shares) | 25,688,062 | 25,353,119 | 24,626,004 | 25,353,119 | 24,312,808 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,108,291 | ||||||||||
Share-Based Payment Arrangement, Expense | $ 3,137 | $ 4,218 | $ 3,381 | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 612 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 407,808 | ||||||||||
Proceeds from Stock Options Exercised | $ 149 | $ 35 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 3,601 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 2 | ||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 25,000 | 86,782 | 69,884 | ||||||||
General and Administrative Expense [Member] | |||||||||||
Class of Warrant or Right, Modification Expense | $ 244 | ||||||||||
Share-Based Payment Arrangement, Expense | $ 2,864 | 3,954 | 2,838 | ||||||||
Research and Development Expense [Member] | |||||||||||
Share-Based Payment Arrangement, Expense | $ 273 | 264 | 543 | ||||||||
Consultant [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 5 years | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 50,000 | ||||||||||
Executive Officer [Member] | |||||||||||
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 1.37 | ||||||||||
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 8.61 | ||||||||||
Executive Officer [Member] | General and Administrative Expense [Member] | |||||||||||
Class of Warrant or Right, Modification Expense | $ 104 | ||||||||||
Share-Based Payment Arrangement, Option [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | ||||||||||
Restricted Stock Units (RSUs) [Member] | |||||||||||
Share-Based Payment Arrangement, Expense | $ 239 | $ 114 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 608 | ||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 6 months | ||||||||||
The 2017 Plan [Member] | Common Stock [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 5,000,000 | ||||||||||
The 2018 Plan [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 663,598 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Share Reserve as a Percent of Outstanding Common Stock | 4% | ||||||||||
The Two Thousand Eighteen Equity Incentive Plan Member | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 207,626 | 25,000 | |||||||||
The 2018 Employee Stock Purchase Plan [Member] | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 623,514 | ||||||||||
Common Stock, Capital Shares Reserved for Future Issuance, Increase (in shares) | 150,000 | ||||||||||
Share-Based Payment Arrangement, Expense | $ 135 | $ 128 | $ 73 | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 1.27 | $ 1.17 | $ 2.5 | ||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 150,000 | ||||||||||
Common Stock, Capital Shares Reserved for Future Issuance, Percentage Increase | 1% | ||||||||||
Employee Stock Purchase Plans, Fair Value of Common Stock Price Per Share on Offering Date, Percentage | 85% | ||||||||||
Employee Stock Purchase Plans, Fair Value of Common Stock Price Per Share on Purchase Date, Percentage | 85% | ||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 86,782 | 69,884 | |||||||||
Employee Stock Purchase Plan (ESPP), Cash Contributions to ESPP | $ 230 | $ 174 | |||||||||
The 2018 Employee Stock Purchase Plan [Member] | Accrued Liabilities [Member] | |||||||||||
Employee-related Liabilities, Current | $ 24 | $ 23 |
Note 8 - Share-based Payment _4
Note 8 - Share-based Payment Awards - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Balance, Options (in shares) | shares | 4,402,292 |
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 4.71 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 1,108,291 |
Issued, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 3.51 |
Exercised, Options (in shares) | shares | (407,808) |
Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 2.23 |
Forfeited/Cancelled, Options (in shares) | shares | (263,549) |
Forfeited/Cancelled, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 5.94 |
Balance, Options (in shares) | shares | 4,839,226 |
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 4.57 |
Outstanding, Weighted Average Remaining Contractual Term (Year) | 7 years 3 months 18 days |
Outstanding, Aggregate Intrinsic Value | $ | $ 3,467 |
Exercisable, Options (in shares) | shares | 3,399,896 |
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 4.78 |
Exercisable, Weighted Average Remaining Contractual Term (Year) | 6 years 8 months 12 days |
Options exercisable at December 31, 2023 | $ | $ 2,432 |
Vested and expected to vest, Options (in shares) | shares | 4,839,226 |
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 4.57 |
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year) | 7 years 3 months 18 days |
Vested and expected to vest, Aggregate Intrinsic Value | $ | $ 3,467 |
Note 8 - Share-Based Payment _5
Note 8 - Share-Based Payment Awards - Schedule of Assumptions Used to Calculate Fair Value of Options Granted (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Expected volatility | 70% | 70% | |
Expected volatility | 70% | ||
Expected volatility | 80% | ||
Risk-free interest rate | 3.50% | 1.50% | 0.90% |
Risk-free interest rate | 4.70% | 3.90% | 1.40% |
Expected term (in years) (Year) | 6 years 3 months 18 days | 5 years 10 months 24 days | 6 years |
Weighted average fair value (in dollars per share) | $ 2.32 | $ 2.32 | $ 5.64 |
Note 8 - Share-based Payment _6
Note 8 - Share-based Payment Awards -Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Outstanding and unvested, balance (in shares) | shares | 369,606 |
Outstanding and unvested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares | $ 2.63 |
Granted (in shares) | shares | 0 |
Granted, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares | $ 0 |
Vested (in shares) | shares | (91,402) |
Vested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares | $ 2.63 |
Forfeited (in shares) | shares | (4,000) |
Forfeited, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares | $ 2.63 |
Outstanding and unvested, balance (in shares) | shares | 274,204 |
Outstanding and unvested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares | $ 2.63 |
Note 9 - Basic and Diluted Ne_3
Note 9 - Basic and Diluted Net Loss per Common Share (Details Textual) - shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 5,418,251 | 5,494,153 | 4,286,687 |
Note 9 - Basic and Diluted Ne_4
Note 9 - Basic and Diluted Net Loss per Common Share - Schedule of Earnings (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Net income (loss) | $ (936) | $ (9,021) | $ (1,955) |
Weighted average number of common shares outstanding, basic and diluted (in shares) | 25,645,366 | 25,145,657 | 25,207,299 |
Net loss per share, basic and diluted (in dollars per share) | $ (0.04) | $ (0.36) | $ (0.08) |
Note 10 - Related-party Trans_2
Note 10 - Related-party Transactions (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Feb. 18, 2019 | Aug. 11, 2017 | May 31, 2021 | Apr. 30, 2021 | Sep. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Proceeds from Sale of Machinery and Equipment | $ 700 | $ 0 | $ 0 | $ 700 | ||||
Gain (Loss) on Disposition of Property Plant Equipment | $ 181 | $ 0 | 0 | $ 181 | ||||
Related Party, Bausch Health [Member] | Royalty [Member] | ||||||||
Related Party Transaction, Rate | 12% | |||||||
Harrow Health Inc [Member] | ||||||||
Common Stock, Shares Owned (in shares) | 1,982,000 | |||||||
Harrow Health Inc [Member] | Eton Pharmaceuticals [Member] | ||||||||
Equity Method Investment, Ownership Percentage | 7.70% | |||||||
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member] | ||||||||
Related Party Transaction, Terms (Year) | 10 years | |||||||
Related Party Transaction, Terms, Renewal (Year) | 2 years | |||||||
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member] | Royalty [Member] | ||||||||
Related Party Transaction, Rate | 10% | |||||||
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member] | Research and Development Expense [Member] | ||||||||
Related Party Transaction, Amounts of Transaction | $ 250 | |||||||
Covenant Based on Sale of First Commercial Product [Member] | Related Party, Eyemax LLC [Member] | ||||||||
Related Party Transaction, Amounts of Transaction | $ 500 | |||||||
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member] | ||||||||
Related Party Transaction, Amounts of Transaction | $ 0 | $ 0 | ||||||
Revenues | $ 1,840 | |||||||
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member] | Covenant Based on Approval by The FDA [Member] | ||||||||
Related Party Transaction, Amounts of Transaction | $ 250 | |||||||
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member] | Covenant Based on Sale of First Commercial Product [Member] | ||||||||
Related Party Transaction, Amounts of Transaction | $ 500 | |||||||
Chief Executive Officer [Member] | Harrow Health Inc [Member] | Restricted Stock Units (RSUs) [Member] | ||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 25,000 |
Note 11 - Leases (Details Textu
Note 11 - Leases (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 30, 2022 | Oct. 31, 2020 | |
Operating Lease, Right-of-Use Asset | $ 92 | $ 188 | $ 188 | $ 195 | |
Operating Lease, Liability | $ 75 | $ 188 | $ 195 | ||
Lessee, Operating Lease, Discount Rate | 7.80% | 8.60% | 5.40% | ||
Operating Lease, Expense | $ 77 | 86 | $ 113 | ||
Operating Lease, Payments | 88 | 88 | 83 | ||
Operating Lease, Right-of-Use Asset, Periodic Reduction | $ 67 | 62 | 88 | ||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 1 year 3 months | ||||
Operating Lease, Weighted Average Discount Rate, Percent | 8.60% | ||||
Research and Development Expense [Member] | |||||
Operating Lease, Cost | $ 0 | 0 | 9 | ||
General and Administrative Expense [Member] | |||||
Operating Lease, Cost | $ 67 | $ 82 | $ 86 |
Note 11 - Leases - Schedule of
Note 11 - Leases - Schedule of Lease-related Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 30, 2022 | Oct. 31, 2020 |
Operating Lease, Right-of-Use Asset | $ 92 | $ 188 | $ 188 | $ 195 |
Liabilities | ||||
Operating lease liabilities, net of current portion | 22 | $ 107 | ||
Total operating lease liabilities | 75 | $ 188 | $ 195 | |
Noncurrent Assets [Member] | ||||
Operating Lease, Right-of-Use Asset | 92 | |||
Accrued Liabilities [Member] | ||||
Liabilities | ||||
Operating lease liabilities, current | $ 53 |
Note 11 - Leases - Schedule o_2
Note 11 - Leases - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Nov. 30, 2022 | Oct. 31, 2020 |
Total | $ 81 | ||
2023 | 58 | ||
2024 | 23 | ||
2025 | 0 | ||
Less: Imputed interest | (6) | ||
Total lease liabilities | $ 75 | $ 188 | $ 195 |
Note 12 - Income Taxes (Details
Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Percentage for Valuation Reserve Against Deferred Tax Assets | 100% | 100% |
Deferred Tax Assets, Gross | $ 21,516 | $ 21,632 |
Operating Loss Carryforwards | 54,190 | |
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | $ 54,190 |
Note 12 - Income Taxes - Schedu
Note 12 - Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Federal | $ 61 | $ 0 | $ 0 |
State | 186 | 0 | 0 |
Total current expense | 247 | 0 | 0 |
Federal | (85) | 2,272 | 460 |
State | (31) | 812 | 185 |
Change in valuation allowance | 116 | (3,084) | (645) |
Total deferred expense | 0 | 0 | 0 |
Income tax expense | $ 247 | $ 0 | $ 0 |
Note 12 - Income Taxes - Compon
Note 12 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Net operating losses | $ 15,447 | $ 17,183 |
Stock-based expenses | 3,372 | 3,090 |
Accruals and other | 2,697 | 1,359 |
Total deferred tax assets | 21,516 | 21,632 |
Valuation allowance | (21,516) | (21,632) |
Net deferred tax assets | $ 0 | $ 0 |
Note 12 - Income Taxes - Sche_2
Note 12 - Income Taxes - Schedule of Reconciliation of Statutory Federal Tax Rate (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Provision (benefit) at statutory rate | 21% | 21% | 21% |
Provision (benefit) at statutory rate | (21.00%) | (21.00%) | (21.00%) |
Permanent items (primarily warrants and stock compensation) | 39.10% | (3.30%) | (2.50%) |
State tax benefit | 6.50% | (8.70%) | (9.50%) |
Federal rate change | 0% | 0% | 0% |
Other items | 0% | 0% | 0% |
Increase (decrease) in valuation allowance | (30.70%) | (33.00%) | (33.00%) |
Increase (decrease) in valuation allowance | 30.70% | 33% | 33% |
Income tax expense | 35.90% | 0% | 0% |
Note 13 - Employee Savings Pl_2
Note 13 - Employee Savings Plan (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 100% | ||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 4% | ||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 242 | $ 172 | $ 154 |
Note 14 - Commitments and Con_2
Note 14 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | ||||||||||||
Sep. 13, 2022 | Oct. 28, 2021 | Jun. 15, 2021 | Mar. 26, 2020 | Nov. 30, 2023 | Oct. 31, 2023 | Jul. 31, 2023 | Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 14, 2023 | Mar. 27, 2020 | Jan. 23, 2019 | |
Share Price (in dollars per share) | $ 2.32 | $ 2.32 | $ 5.64 | |||||||||||
Research and Development Expense, Total | $ 3,322 | $ 3,996 | $ 6,235 | |||||||||||
Cost of Goods and Services Sold | 10,581 | 6,933 | 2,827 | |||||||||||
Common Stock [Member] | ||||||||||||||
Share Price (in dollars per share) | $ 3.33 | |||||||||||||
Indemnification Rights and Agreements [Member] | ||||||||||||||
Other Commitment, Total | 0 | 0 | ||||||||||||
License [Member] | ||||||||||||||
Cost of Goods and Services Sold | 1,000 | 1,640 | 1,500 | |||||||||||
Carglumic Acid Tablets [Member] | ||||||||||||||
Payments to Acquire Marketing Rights | $ 3,250 | |||||||||||||
Commitment, Allocation of Profits, Percentage | 50% | |||||||||||||
Betaine Anhydrous [Member] | ||||||||||||||
Payments to Acquire Marketing Rights | $ 2,000 | $ 125 | ||||||||||||
Commitment, Allocation of Profits, Percentage | 65% | |||||||||||||
Betaine Anhydrous [Member] | Obligation Based on Commercial Success [Member] | ||||||||||||||
Other Commitment, Total | $ 1,000 | |||||||||||||
FDA-Approved ANDA For Nitisinone [Member] | ||||||||||||||
Payments to Acquire Marketing Rights | $ 150 | |||||||||||||
Commitment, Allocation of Profits, Percentage | 80% | |||||||||||||
FDA-Approved ANDA For Nitisinone [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member] | ||||||||||||||
Payments to Acquire Marketing Rights | $ 500 | |||||||||||||
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | ||||||||||||||
Revenue, Additional Based on Event and Sales-based Milestones Achievements | $ 5,500 | |||||||||||||
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | Milestone Method [Member] | ||||||||||||||
Revenues | 27,500 | |||||||||||||
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member] | ||||||||||||||
Other Commitment, Total | $ 450 | |||||||||||||
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member] | ||||||||||||||
Other Commitment, Total | $ 200 | |||||||||||||
Royalties, Percentage of Net Sales, | 12.50% | |||||||||||||
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member] | ||||||||||||||
Other Commitment, Total | $ 250 | |||||||||||||
Royalties, Percentage of Net Sales, | 17% | |||||||||||||
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Topiramate (fka ET-101) [Member] | ||||||||||||||
Accounts Receivable, after Allowance for Credit Loss, Total | $ 5,000 | |||||||||||||
Liqmeds Worldwide Limited (“LMW”) [Member] | Licensing and Supply Agreement (the “Agreement”) [Member] | Obligation Based on Issuance of Orange-book Listed Patent [Member] | ||||||||||||||
Other Commitment, Total | $ 650 | |||||||||||||
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | ||||||||||||||
Aggregate Value of Licensing Milestone Included in Research and Development Expense | $ 1,000 | |||||||||||||
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Common Stock [Member] | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 379,474 | |||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,264 | |||||||||||||
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Obligation Based on Exclusivity Status from FDA [Member] | ||||||||||||||
Other Commitment, Total | $ 2,500 | |||||||||||||
Diurnal Limited [Member] | License [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | ||||||||||||||
Commitment, Milestone Fee | $ 3,500 | |||||||||||||
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | ||||||||||||||
Research and Development Expense, Total | $ 500 | |||||||||||||
Royalty on Net Sales of Products, Percent | 10% | |||||||||||||
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Development Milestones [Member] | ||||||||||||||
Other Commitment, Total | $ 3,500 | |||||||||||||
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Commercial Success [Member] | ||||||||||||||
Other Commitment, Total | $ 6,000 | |||||||||||||
Dr. Reddy’s [Member] | License [Member] | ||||||||||||||
Revenues | $ 5,000 | |||||||||||||
Sintetica [Member] | ||||||||||||||
Cost of Goods and Services Sold | $ 812 |